Company intelligence / Profile preview

DexTech Medical AB

Ownership: Private
Development stage: Other

Overview

OsteoDex, the lead candidate for castration-resistant prostate cancer with bone metastases, has completed a successful Phase 2 study showing high tolerability, mild side effects, and treatment effect in patients who failed existing drugs. The company aims to out-license its drug candidates after completion of Phase 2 studies.

Therapeutic areas: Oncology
Modalities: Small moleculeModified carbohydrate molecule-based drugs
Industry: Biotech

Drug pipeline

3 assets

OsteoDex

2 more assets in the full pipeline.

Request access →

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of June 2025.

Beyond the preview

Go deeper on DexTech Medical AB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DexTech Medical AB.

Explore the full profile